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In Vivo Butyrylcholinesterase Activity Is Not
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Objective: We tested the premise that cholinesterase inhibitor therapy should target butyrylcholinesterase (BuChE) in
Alzheimer’s disease (AD), not acetylcholinesterase (AChE) alone, because both enzymes hydrolyze acetylcholine, and
BuChE is increased in AD cerebral cortex. Methods: To examine this issue in vivo, we quantified human cerebral cortical
BuChE activity using tracer kinetic estimates (k3) of 1-[
11C]methyl-4-piperidinyl n-butyrate ([11C]BMP) hydrolysis de-
termined by positron emission tomography. Validation of the putative positron emission tomography method included
regional distribution, positive correlation with age, and attenuation by the nonselective cholinesterase inhibitor phy-
sostigmine, but no attenuation by the AChE-selective inhibitor donepezil. Positron emission tomography scans in AD
patients (n  15) and control subjects (n  12) measured both BuChE (using [11C]BMP) and AChE activity (using
N-[11C] methylpiperidin-4-yl propionate, an established method). Results: As expected, AChE activity in AD cerebral
cortex was decreased to 75  13% of normal (p  0.00001). Contrary to prediction, accompanying BuChE activity also
was decreased to 82  14% of normal (p  0.001). Interpretation: Failure to observe increased [11C]BMP hydrolysis in
vivo makes it less likely that incremental BuChE contributes importantly to acetylcholine hydrolysis in AD. The findings
do not support the premise that inhibitor therapy should target BuChE so as to prevent increased levels of BuChE from
hydrolyzing acetylcholine in AD cerebral cortex.
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There are two principal cholinesterases in the human
brain, acetylcholinesterase (AChE; EC 3.1.1.7) and bu-
tyrylcholinesterase (BuChE; EC 3.1.1.8). AChE is
membrane bound predominantly on presynaptic cho-
linergic neurons, but is also on postsynaptic cholino-
ceptive neurons.1 BuChE has a neuroglial distribu-
tion.2,3 The physiological role of AChE is to terminate
the synaptic action of acetylcholine (ACh) through cat-
alytic hydrolysis. ACh is hydrolyzed by both AChE
and BuChE, but AChE catalyzes the hydrolysis of ACh
much more efficiently than BuChE.4 The physiological
role of BuChE is poorly understood, particularly in the
central nervous system. Recent attention has focused
on this enigmatic enzyme and its possible relevance in
the treatment of Alzheimer’s disease (AD).5–11
Cholinesterase inhibitors have shown greater efficacy
than placebo in clinical trials and are widely prescribed
as symptomatic treatment to improve cognition and
behavior in AD patients with mild or moderate de-
mentia. The basis is the presynaptic cholinergic deficit
that is found consistently in AD cerebral cortex.12–14
The rationale is to increase the availability of ACh
within cholinergic synapses by reducing its hydrolysis.
Opinion differs on the issue whether these drugs
should be selective inhibitors of AChE alone (eg, done-
pezil) or nonselective inhibitors of both AChE and
BuChE (eg, rivastigmine). In the absence of cholinest-
erase inhibitors that are selective for BuChE, the po-
tential efficacy of BuChE inhibition has been difficult
to establish from clinical trials.7,15 Proponents of
AChE-selective inhibitors claim less peripheral adverse
effects,16,17 whereas some reject these results.18 Propo-
nents of nonselective inhibitors argue that if only
AChE is inhibited, ACh will continue to be hydrolyzed
by uninhibited BuChE that is known to be increased
in AD cerebral cortex.5–11 However, the magnitude
and clinical significance of this process has not yet been
established in vivo.16
To explore this issue directly, we tested the hypoth-
esis that in vivo measures in cerebral cortex of AD pa-
tients with mild or moderate dementia would demon-
strate the same discordant relation between AChE
(decrease) and BuChE activity (increase) as has been
documented from in vitro studies of postmortem AD
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brain.2,9,19–23 First, we identified 1-[11C]methyl-4-
piperidinyl n-butyrate ([11C]BMP) as a ligand superior
for the in vivo measurement of cerebral BuChE activity
based on specificity determined by in vitro assay and
pharmacokinetics determined by in vivo measurements
in primate brain.24 Next, we validated the quantitative
measure of in vivo human cerebral cortical BuChE ac-
tivity using tracer kinetic estimates of [11C]BMP hydro-
lysis determined by positron emission tomography
(PET). Finally, we performed PET scans in AD patients
and in healthy control subjects to measure both BuChE
activity, using [11C]BMP, and accompanying AChE ac-
tivity, using N-[11C]methylpiperidin-4-yl propionate
([11C]PMP), a previously established method.25–30 Re-
cently, Roivainen and colleagues31 reported using
[11C]BMP with PET to map BuChE activity in human




A young control group consisted of 13 healthy subjects
across an age range from 20 to 47 years (mean age, 30  9
years; 4 female and 9 male subjects) and an elderly control
group consisted of 12 healthy subjects across an age range
from 55 to 68 years (mean age, 62  7 years; 8 female and
4 male subjects). Healthy subjects had no history of signifi-
cant general medical, neurological, or psychiatric illness, head
injury with loss of consciousness, or drug or alcohol depen-
dence, and they were not taking any medications with cen-
tral nervous system actions. An AD group consisted of 15
subjects across an age range from 59 to 82 years (mean age,
73  8 years; 9 female and 6 male subjects). AD subjects
were not taking any medications with actions known to af-
fect the central cholinergic system. All were required to be
mildly or moderately demented and to have a clinical diag-
nosis of probable AD.32 Mean Clinical Dementia Rating33
was 1.1  0.4. Mean Mini-Mental State Examination34
score was 19  4. This study was approved by an institu-
tional review board. Written, informed consent was obtained
from all subjects or their caregivers.
Radiotracers
Details of preparation of [11C]BMP24 and [11C]PMP27 have
been reported. In vitro assays have characterized piperidinyl
esters as substrates for AChE and BuChE.24–26,35 [11C]PMP
is a selective substrate for AChE, with a selectivity in ex vivo
cholinesterase assays of 97% for AChE.25 [11C]BMP is not a
substrate for AChE.
Scan Protocols and Analysis
Data were acquired using a PET scanner (Siemens ECAT
EXACT-47; CTI, Knoxville, TN) in three-dimensional
mode. Final image resolution was 10.0mm (full-width at
half-maximum) in-plane and axially. Each radiotracer was in-
jected intravenously as a 444MBq (12mCi) dose. We limited
a [11C]BMP dose arbitrarily to a total injected mass less than
25m/70 kg person. When used sequentially on the same
day, [11C]BMP was injected first, and then [11C]PMP was
injected after an interval of 2 hours. Tracer input functions
were determined from serial blood samples withdrawn
through a radial artery catheter. The fraction of unmetabo-
lized tracer in plasma samples was determined. Data acqui-
sition and analysis were performed as reported previously.30
A three-compartment model28,29 was used to yield pixel-by-
pixel estimates of the rate constant k3, which represented the
hydrolysis rate (activity) of either BuChE or AChE. Regional
values of k3 were extracted using the three-dimensional ste-
reotactic surface projection technique.36 Data were not cor-
rected for partial-volume effects. Any effect of cerebral cor-
tical atrophy should account for less than an 8% reduction
in the kinetically estimated values of [11C]BMPk3 or
[11C]PMPk3.
28 Statistical methods included two-sample t
tests assuming equal variances and different sample sizes for
minimum detectable differences, two-tailed paired and un-
paired t tests of significance, and two-factor repeated-
measures analysis of variance. Reproducibility was estimated
for test-retest variability, that is, the absolute difference in
measured activity between the test and the retest divided by
the average of the two studies and expressed as a percentage.
Inhibition Protocols
Validation included measuring cerebral cortical responses of
[11C]BMP k3 and [
11C]PMP k3 after treatment with well-
characterized drugs37,38 known to be selective (donepezil)
and nonselective (physostigmine) cholinesterase inhibitors.
Young control subjects were scanned with [11C]BMP (n 
4) or [11C]PMP (n  5)28 before and after a constant rate
infusion of physostigmine salicylate (Antilirium TM; Forest
Pharmaceuticals, St. Louis, MO) in a dose of 1.5mg in
100ml saline over a period of 60 minutes.28 Four AD pa-
tients (CDR1) were scanned with both [11C]BMP and
[11C]PMP before and after treatment with donepezil hydro-
chloride (5mg/day; Aricept TM; Pfizer, New York, NY) for a
2- to 6-month period. After treatment, k3 data were ex-
pressed as percentage decrease from pretreatment values (in-
hibition).
Alzheimer’s Disease Protocol
Both a [11C]BMP and a [11C]PMP PET scan were per-
formed on each elderly control subject (n  12) and AD
subject (n  15) to quantify in vivo BuChE activity and
accompanying AChE activity in normal and AD cerebral
cortex.
Results
Validity of the 1-[11C]Methyl-4-piperidinyl n-
Butyrate Method
REPRODUCIBILITY. In cerebral cortex of elderly control
subjects, the coefficients of variation for intersubject
(n  12) measurements of [11C]BMP k3 and
[11C]PMP k3 were 11 and 12%, respectively. Intrasu-
bject test-retest measures made at 2-month intervals us-
ing [11C]BMP (n  5) and [11C]PMP (n  6) dif-
fered by 7  5 and 6  3%, respectively.
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DISTRIBUTION. Our in vivo measures of [11C]BMP k3
and [11C]PMP k3 (Table) in healthy control cases
agreed well with relative regional distributions of
BuChE and AChE activity based on biochemical assay
of postmortem human brain.39 BuChE activity ranged
from low in cerebral cortex to 2.5 times higher in cer-
ebellum (Fig 1), and AChE activity ranged from low in
cerebral cortex to 21 times higher in caudate nucleus.
AGE AND SEX. Cerebral cortical [11C]BMP k3 in-
creased with age, whereas [11C]PMP k3 did not,
28 a
finding in agreement with biochemical assays of post-
mortem brain.19,23 [11C]BMP k3 in total cerebral cor-
tex averaged 25% higher in elderly (age, 62  7 years;
n  12) than in young (age, 30  9 years; n  13)
subjects. Between either the age groups or the sex
groups, the minimum detectable difference was 14%
(80% power at p  0.05). Using a two-factor analysis
of variance (age and sex as factors), we noted a signif-
icant age effect (p  0.009), with [11C]BMP k3 in-
creasing with age. Neither sex effect (p  0.15) nor
age by sex interaction (p  0.17) were significant. Rel-
ative to parietal cortex distribution, regional [11C]BMP
k3 cerebral cortical distributions (frontal, temporal, oc-
cipital, visual, posterior cingulate) did not differ signif-
icantly (p  0.1) between young and elderly subjects.
RESPONSE TO INHIBITORS. As predicted, acute admin-
istration of the nonselective inhibitor physostigmine
(1.5mg infusion) inhibited both BuChE and AChE
significantly in normal cerebral cortex (Fig 2). BuChE
inhibition measured with [11C]BMP (n  4) was
49  6% (p  0.001), and AChE inhibition measured
with [11C]PMP (n  5) was 52  9% (p 
0.0002).28 The inhibition levels of the two cholinest-
erases did not differ significantly (p  0.6). As pre-
dicted, treatment with the selective AChE inhibitor
donepezil (5mg/day for 2–6 months; n  4) inhibited
only AChE in AD cerebral cortex (see Fig 2). BuChE
inhibition measured with [11C]BMP was 4  12%
and was not significant (p  0.5). Accompanying
AChE inhibition measured with [11C]PMP was 27 
5% and was significant (p  0.003).
Alzheimer’s Disease
When [11C]BMP and [11C]PMP PET scans were com-
pared (Fig 3) between elderly control subjects (n  12)
and AD patients (n  15), in vivo AChE activity in
overall AD cerebral cortex was found to be decreased
to 75  13% of normal (p  0.00001). Associated in
vivo BuChE activity was not found increased, but in-
stead was decreased to 82  14% of normal (p 
0.001). The minimum detectable difference in cerebral
cortex between elderly control subjects and AD pa-
tients was 13% with [11C]BMP k3 and 12% with
[11C]PMP k3 (80% power at p  0.05). The differ-
ence between [11C]BMP k3 decrease (mean, 18%) and
[11C]PMP k3 decrease (mean, 25%) was significant
(p  0.05). The difference between the ratio
[11C]BMPk3/[
11C]PMPk3 measured in normal
(0.94  0.13) and in AD cerebral cortex (1.04 
0.17) was not significant (p  0.13). As noted earlier,
no compensatory increase in BuChE activity accompa-
















Cerebellum 2.50  0.39 2.90  0.04 8.97  2.00 12.0  2.2
Putamen 1.74  0.11 20.7  3.6
Caudate nucleus 1.58  0.10 1.97  0.23 21.4  4.6 54.7  6.7
Thalamus 1.28  0.12 2.60  0.31
Pons 1.14  0.14 5.44  1.24
Cerebral cortex
Frontal cortex 0.93  0.06 1.05  0.07
Temporal cortex 0.91  0.04 1.47  0.35 1.06  0.08 1.5  0.3
Occipital cortex 0.99  0.05 0.96  0.05
Visual cortex 0.96  0.08 0.94  0.06
Posterior cingulate cortex 0.99  0.07 1.10  0.08
Parietal cortex 1.00  0.00 1.00  0.25 1.00  0.00 1.0  0.1
Relative activity indices are relative to the corresponding parietal cortex measure. In vivo butyrylcholinesterase (BuChE) and acetylcholinesterase
(AChE) activities were determined and were normalized to the parietal cortex measure in each elderly healthy control subject (n  12).
Postmortem indices were calculated from the published data of Atack and colleagues.39 Activities in each elderly control brain (n  3-5) were
normalized to the mean parietal cortex measure.
aThe rate constant k*3 represents cholinesterase activity, where the asterisk means relative to the parietal cortex.
SD  standard deviation; [11C]BMP  1-[11C]methyl-4-piperidinyl n-butyrate; [11C]PMP  N-[11C]methylpiperidin-4-yl propionate.
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nied selective inhibition of AChE activity in AD cor-
tex.
Discussion
In vivo AD brain did not demonstrate the substantial
increase in BuChE activity predicted from in vitro
studies of postmortem AD brain.2,9,19–23 Because we
found that the activities of both cholinesterases were
decreased in AD cerebral cortex, there was no in vivo
evidence of the high ratios of BuChE/AChE that have
been proposed as regional markers of AD by in vitro
studies.2,6 In addition, BuChE activity did not increase
in human brain after months of selective AChE inhi-
bition, an observation that was consistent with the re-
ported absence of compensatory increase in BuChE ac-
tivity in AChE-devoid brains of knock-out mice.40
We interpreted our results to be evidence that the
incremental buildup of BuChE that is identified in
postmortem AD brain does not contribute substantially
to neuropil-associated BuChE activity in the living AD
brain. We considered and rejected some alternative ex-
planations. First, were the in vitro reports incorrect?
We consider this unlikely. In vitro evidence is convinc-
ing from studies performed in multiple laboratories
and with differing approaches that BuChE is increased
in postmortem AD cerebral cortex. The in vivo neuro-
chemical role and consequence of this incremental
BuChE, however, has been speculative. An early study
based on quantitative biochemical measures in autop-
sied brain found that total AChE was reduced 33% in
AD temporal cortex, but total BuChE was increased
40%.19 Histochemistry demonstrates both AChE and
BuChE are bound to pathological AD substructures.20
For example, BuChE emerges from neuroglia2 and ac-
cumulates in pathological plaques, neurofibrillary tan-
gles, and vessels affected by congophilic angiopa-
Fig 1. Parametric images of 1-[11C]methyl-4-piperidinyl n-butyrate ([11C]BMP) kinetics within three brain levels of a healthy con-
trol subject, all normalized to mean values in parietal cortex. The rate constant K*3 represents delivery, and the rate constant k*3
represents butyrylcholinesterase activity, where the asterisk means relative to the parietal cortex. Compared with cerebral cortex, bu-
tyrylcholinesterase activity is higher in cerebellum, striatum, thalamus, and subcortical white matter, where it is localized in glial
cells.39
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thy.2,20,22,23 This accumulation, especially that enzyme
bound to mature compact neuritic plaques,41 is con-
sidered to account for the incremental BuChE ob-
served in AD cerebral cortex tissue hemogenates.23 In
support of this distinction, no increase was found in
BuChE immunochemistry associated with histologi-
cally normal AD neuropil, where cholinergic neuro-
transmission occurs.9,21
Second, did we scan our AD patients with mild or
moderate dementia too early in the course of their dis-
ease for incremental plaque-bound BuChE to be ex-
pected? This is unlikely. The mature compact neuritic
plaques that are reported to express increased BuChE
activity41 and the presynaptic cholinergic deficit are es-
tablished already even earlier in the course of AD, be-
fore the onset of clinical symptoms.42
Third, did a mismatched control group obscure
BuChE activity gain? The AD group (mean age, 73
years) was older than the elderly control group (mean
age, 62 years), and BuChE activity increased with age
in the control subjects (25% over 32 years). Such a
bias would favor underestimating reduction, not gain,
in BuChE activity. Accounting for this would equalize
the BuChE and AChE declines in AD cerebral cortex
to 75  13% of normal.
Finally, was the [11C]BMP PET measure flawed? Its
rationale is based on the acetylcholine-analog PET
method of Irie and colleagues.25 This method has
been accepted widely as a valid direct measure to quan-
tify in vivo AChE.28,30,43–45 Data reported here and
previously24,31 support the validity of the new
[11C]BMP PET measure as a method appropriate to
the in vivo assessment of BuChE activity associated
with cholinergic terminals. However, tissue heterogene-
ity on an anatomical scale below PET imaging resolu-
tion can complicate quantification of enzyme activity
in foci distant from these terminals. For example, even
though tissue homogenate assays might measure scarce,
but highly concentrated, foci of incremental plaque
BuChE that were sparsely perfused, this PET method
would underestimate their activity, because delivery of
[11C]BMP tracer to the plaque enzyme would be lim-
ited. Nevertheless, the [11C]BMP PET method serves
well to measure BuChE activity that is associated with
Fig 2. Positron emission tomography (PET) scans using 1-[11C]methyl-4-piperidinyl n-butyrate ([11C]BMP) and
N-[11C]methylpiperidin-4-yl propionate ([11C]PMP) quantified correctly the in vivo inhibition of butyrylcholinesterase (BuChE) and
acetylcholinesterase (AChE) activities expected after treatment with nonselective and selective cholinesterase inhibitor drugs. After
acute administration of the nonselective inhibitor physostigmine, mean inhibition in cerebrocortical, striatal, thalamic, and pontocer-
ebellar zones was 49, 50, 54, and 51%, respectively, for BuChE (n  4) and 52, 44, 61, and 64%, respectively, for AChE (n 
5). After treatment for several months with the selective AChE inhibitor donepezil (n  4), AChE inhibition in the same zones
was 27, 31, 36, and 46%, respectively, but BuChE was not inhibited in any zone. Image summations are right-left averages of
percentage decrease from pretreatment values (percentage inhibition) plotted as three-dimensional stereotactic surface projections (ref-
erence anatomic map [REF]). Red color represents greater inhibition of BuChE or AChE by physostigmine or donepezil. AD 
Alzheimer’s disease.
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cholinergic terminals, and these are the critical sites
where ACh is concentrated and where cholinesterase
inhibition affects cholinergic neurotransmission.
ACh hydrolysis occurs predominantly within cholin-
ergic synapses by outwardly facing, membrane-
anchored, tetrameric (G4) molecular forms of AChE
and BuChE.46 Evidence for hydrolysis by BuChE is
indirect. First, BuChE can hydrolyze ACh, but is less
efficient than AChE.4 Second, inhibition of BuChE in
rat brain leads to a dose-dependent increase in ACh
concentration in microdialysate.6 Third, complete in-
hibition of both AChE and BuChE is fatal, but AChE-
null knock-out mice survive, presumably because
BuChE hydrolyzes ACh and prevents cholinergic over-
activity.40 Fourth, when AChE is inhibited in tissue
sections, BuChE hydrolyzes the ACh surrogate acetyl-
thiocholine iodide.9 The actual contribution of
terminal-associated BuChE to overall molar hydrolysis
rate of ACh in living human cerebral cortex has yet to
be quantified. But the incremental BuChE discovered
in vitro in AD cerebral cortex is plaque-bound enzyme
in the embryonic G1 molecular form,21 not the
membrane-anchored G4 BuChE that is considered to
play a role in synaptic hydrolysis of ACh.46
There is no good evidence that plaque-bound cho-
linesterases, whether BuChE or AChE, hydrolyze en-
dogenous ACh in the in vivo human brain. In quanti-
tative comparisons, regional losses of cholinergic
terminals and AChE activity did not differ throughout
the in vivo AD cerebral cortex.28 If in vivo AChE ac-
tivity was bolstered strongly by incremental plaque-
bound AChE, terminal loss should have been dispro-
portionate to AChE activity loss, but it was not.
Our results suggest that, in AD, the hydrolysis of
synaptic ACh by membrane-anchored G4 BuChE de-
clines and is little affected by the buildup of the G1
BuChE that is found bound to neuritic plaques, neu-
rofibrillary tangles, and vessels affected by congophilic
angiopathy. In postmortem AD cerebral cortex, G4
forms of both AChE and BuChE are selectively
lost,21,47 and G4 AChE is decreased more than is G4
BuChE.21 Our in vivo PET data are consistent with
those in vitro data.
Consequently, our results did not support the
premise that inhibitor therapy should target BuChE to
prevent increased levels of BuChE from hydrolyzing
ACh in AD cerebral cortex.6,7,9 In normal brain, only
a small amount of ACh is hydrolyzed by BuChE. Most
ACh hydrolysis is catalyzed by AChE, which hydro-
lyzes ACh much more efficiently than does BuChE. In
AD brain, we found that terminal-associated BuChE
activity was not increased in vivo, rather it was de-
creased. In addition, we found that no compensatory
increase occurred in terminal-associated BuChE activity
after months of AChE inhibition therapy. The primacy
of AChE inhibition as cholinomimetic therapy in AD
is further supported by recent comparative clinical tri-
als that show no difference in efficacy for cognitive im-
provement between AChE-selective (donepezil) and
nonselective (rivastigmine) cholinesterase inhibi-
tors.48,49 Yet, current therapeutic drugs provide only
about 30% inhibition of in vivo AChE activity in ce-
Fig 3. Contrary to in vitro evidence that butyrylcholinesterase (BuChE) is increased substantially in Alzheimer’s disease (AD) cere-
bral cortex, in vivo BuChE activity was not found to be increased. Positron emission tomography scans were performed in elderly
control subjects (n  12) and in AD patients (n  15) using 1-[11C]methyl-4-piperidinyl n-butyrate ([11C]BMP) and
N-[11C]methylpiperidin-4-yl propionate ([11C]PMP) to measure BuChE and acetylcholinesterase (AChE) activities, respectively. In
cerebral cortical, striatal, thalamic, and pontocerebellar zones of in vivo AD brain, activity reductions averaged 28% for AChE and
18% for BuChE. Image summations are right-left averages of percentage reductions from normal plotted as three-dimensional stereo-
tactic surface projections (reference anatomic map [REF]). Red color represents greater reductions of BuChE or AChE in AD in
comparison with elderly control subjects.
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rebral cortex.30,43–45 For more efficient reduction of
ACh hydrolysis, drug development would be better tar-
geted to increasing AChE inhibition without serious
adverse effects, rather than to increasing BuChE inhi-
bition.
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